60 Degrees seeks FDA voucher for babesiosis drug
SXTP outlines its FDA priority-voucher request and clinical path that could make tafenoquine the first approved babesiosis treatment around the 2027 tick season.
Rhea-AI Filing Summary
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reports that on September 12, 2026 it submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) to treat babesiosis, a tick-borne parasitic disease with no FDA-approved therapy. The company highlights published case reports in treatment‑refractory babesiosis showing cure rates of about 83% when tafenoquine is added to atovaquone-based therapy, and confirms that all three currently evaluable patients in its FDA‑authorized expanded access study have been cured.
The company is conducting a randomized, double‑blind, placebo‑controlled trial (NCT06207370), with enrollment for a prespecified interim analysis complete and a DSMB review scheduled for October 1, 2026. Depending on that outcome, it plans either regular approval based on the trial or accelerated approval supported by expanded‑access and published data, targeting an sNDA submission in March–April 2027. The company states that CNPV review could allow tafenoquine to become the first FDA‑approved babesiosis treatment by or before the 2027 tick season, and it commits to manufacture more than 50% of the value of any CNPV‑supported products in the U.S. and to provide volume‑based discounts to federal programs.
Positive
- Clear regulatory roadmap for tafenoquine in babesiosis, including a completed-enrollment randomized trial, an FDA-authorized expanded access study, and a stated target for sNDA submission in March–April 2027.
- Encouraging early efficacy signals in treatment-refractory babesiosis, including approximately 83% cure in published case reports and cures in all three evaluable patients in the expanded access study, if replicated, could underpin a strong approval case.
- Potential priority review via CNPV could accelerate availability of what the company positions as a first FDA-approved babesiosis treatment by or before the 2027 tick season, improving commercial and clinical adoption timing.
Negative
- Regulatory and clinical outcomes remain uncertain, as the path depends on the October 1, 2026 DSMB interim analysis, sufficiency of clinical data, and FDA decisions on both the CNPV request and eventual sNDA.
- Execution and funding risks are highlighted, including the need to manufacture tafenoquine for commercial distribution and to secure funding for clinical development, regulatory activities, and commercialization.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
CNPV Statement of Interest date: September 12, 2026
Published case report cure rate: Approximately 83%
Expanded access cured patients: 3 patients
+3 more
6 metrics
CNPV Statement of Interest date
September 12, 2026
Date SXTP submitted its Statement of Interest to the FDA for a Commissioner’s National Priority Voucher
Published case report cure rate
Approximately 83%
Cure rate in relapsing babesiosis patients when tafenoquine was added to atovaquone-based therapy
Expanded access cured patients
3 patients
Number of currently evaluable patients cured in the FDA-authorized expanded access study NCT06478641
DSMB interim analysis date
October 1, 2026
Scheduled date for the Data Safety Monitoring Board review of trial NCT06207370
Target sNDA submission window
March–April 2027
Planned timing for submitting the supplemental New Drug Application for tafenoquine in babesiosis
U.S. manufacturing commitment
More than 50%
Share of the value of future CNPV-supported products that SXTP commits to manufacture in the United States
Key Terms
Commissioner’s National Priority Voucher, expanded access study, Data Safety Monitoring Board, accelerated approval, +1 more
5 terms
Commissioner’s National Priority Voucher regulatory
"requesting a Commissioner’s National Priority Voucher (“CNPV”) designated"
expanded access study medical
"the Company’s FDA-authorized randomized placebo-controlled trial and an expanded access study"
An expanded access study is a regulated program that allows patients to receive an experimental drug or medical device outside a formal clinical trial when no approved options exist, under close oversight. Think of it like a controlled “test drive” for people who can’t join the main trials; for investors it can affect perceived demand, early safety signals, regulatory momentum and potential future sales, but it doesn’t replace randomized clinical trials.
Data Safety Monitoring Board medical
"the Data Safety Monitoring Board (“DSMB”) analysis is scheduled"
A data safety monitoring board is a group of experts who regularly review information from a research or testing process to ensure it is safe and ethical. Think of them as watchdogs that watch over ongoing projects to protect participants and ensure everything is proceeding correctly. Their oversight helps maintain trust and safety, which is important for investors who want to see responsible management and reliable results.
accelerated approval regulatory
"either regular approval supported by the randomized trial or accelerated approval supported"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
standard of care medical
"tafenoquine plus standard of care versus placebo plus standard of care"
Standard of care is the accepted medical treatment or clinical approach that most qualified doctors would use for a given condition today, based on available evidence, guidelines and common practice. For investors, it acts like the baseline product customers expect: a new therapy or device must match or improve on the standard of care to win market share, gain reimbursement and limit legal or regulatory risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did 60 DEGREES PHARMACEUTICALS (SXTP) announce in this 8-K?
The company reported submitting a Statement of Interest to the FDA on September 12, 2026 requesting a Commissioner’s National Priority Voucher for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) to treat babesiosis.
What clinical data does SXTP report for tafenoquine in babesiosis?
SXTP cites published case reports where tafenoquine added to atovaquone-based therapy achieved about 83% cure in relapsing patients, approaching 100% with sustained treatment, and reports that all three currently evaluable patients in its expanded access study have been cured.
What is the status of SXTP’s randomized babesiosis trial (NCT06207370)?
The company states that enrollment needed for the prespecified interim analysis is complete in its randomized, double-blind, placebo-controlled trial, and the Data Safety Monitoring Board review is scheduled for October 1, 2026.
What regulatory timeline does SXTP target for tafenoquine in babesiosis?
Depending on the interim analysis, SXTP plans to seek either regular or accelerated approval and targets a supplemental NDA submission in March–April 2027, with CNPV review potentially allowing approval by or before the 2027 tick season.
What manufacturing and pricing commitments does SXTP describe?
SXTP commits to manufacture more than 50% of the value of any CNPV‑supported products in the United States and to provide volume-based discounts to federal programs.
Why is babesiosis a focus for SXTP’s tafenoquine program?
The company describes babesiosis as an expanding tick-borne parasitic infection in the U.S. with no FDA-approved therapy, posing particular danger to immunocompromised patients who may have prolonged or relapsing infections and increased mortality.
AI-generated analysis. How Rhea-AI works. Not financial advice.
